EP1165093A4 - Method for validating/invalidating target(s) and pathways - Google Patents

Method for validating/invalidating target(s) and pathways

Info

Publication number
EP1165093A4
EP1165093A4 EP00913730A EP00913730A EP1165093A4 EP 1165093 A4 EP1165093 A4 EP 1165093A4 EP 00913730 A EP00913730 A EP 00913730A EP 00913730 A EP00913730 A EP 00913730A EP 1165093 A4 EP1165093 A4 EP 1165093A4
Authority
EP
European Patent Office
Prior art keywords
invalidating
validating
pathways
target
invalidating target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00913730A
Other languages
German (de)
French (fr)
Other versions
EP1165093A1 (en
Inventor
Jonathan W Nyce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epigenesis Pharmaceuticals Inc
Original Assignee
Epigenesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epigenesis Pharmaceuticals Inc filed Critical Epigenesis Pharmaceuticals Inc
Publication of EP1165093A1 publication Critical patent/EP1165093A1/en
Publication of EP1165093A4 publication Critical patent/EP1165093A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
EP00913730A 1999-03-05 2000-03-02 Method for validating/invalidating target(s) and pathways Withdrawn EP1165093A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12295099P 1999-03-05 1999-03-05
US122950P 1999-03-05
PCT/US2000/005643 WO2000051621A1 (en) 1999-03-05 2000-03-02 Method for validating/invalidating target(s) and pathways

Publications (2)

Publication Number Publication Date
EP1165093A1 EP1165093A1 (en) 2002-01-02
EP1165093A4 true EP1165093A4 (en) 2002-07-24

Family

ID=22405857

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00913730A Withdrawn EP1165093A4 (en) 1999-03-05 2000-03-02 Method for validating/invalidating target(s) and pathways

Country Status (10)

Country Link
EP (1) EP1165093A4 (en)
JP (1) JP2002537792A (en)
KR (1) KR20020068262A (en)
CN (1) CN1348376A (en)
AU (1) AU3512300A (en)
BR (1) BR0009247A (en)
CA (1) CA2366055A1 (en)
IL (1) IL145034A0 (en)
MX (1) MXPA01008870A (en)
WO (1) WO2000051621A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894021B2 (en) 2000-02-17 2005-05-17 Cv Therapeutics, Inc. Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation
DE10346487A1 (en) * 2003-10-02 2005-05-12 Transmit Technologietransfer Process for the preparation of a cell and / or tissue and / or disease phase specific drug
EP2426206B8 (en) 2006-02-13 2018-10-31 Monsanto Technology LLC Selecting and stabilizing dsRNA constructs
WO2008022349A2 (en) 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
DE102007021443A1 (en) * 2007-05-08 2008-11-13 Brahms Aktiengesellschaft Diagnosis and risk stratification using NT-proET-1
US8974791B2 (en) 2007-07-27 2015-03-10 Armagen Technologies, Inc. Methods and compositions for increasing α-L-iduronidase activity in the CNS
WO2010108048A2 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
CN102169121B (en) * 2010-02-25 2013-12-04 北京诺赛基因组研究中心有限公司 New application of human kinase SBK1 (SH3-binding domain kinase 1)
EP3711778A1 (en) 2011-12-02 2020-09-23 Armagen, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
US10906981B2 (en) 2013-07-19 2021-02-02 The Regents Of The University Of California Compositions and methods related to structures that cross the blood brain barrier
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
PL3093022T3 (en) 2015-05-15 2020-02-28 Sterna Biologicals Gmbh & Co. Kg Gata-3 inhibitors for use in the treatment of th2-driven asthma
CN114480406B (en) * 2021-09-16 2024-01-30 广东翠点生物科技有限公司 IL-1 signal path response element and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042178A2 (en) * 1999-01-13 2000-07-20 Dupont Pharmaceuticals Company Antagonist blockade of crf2 receptors for the treatment of psy chiatric disorders and the use of chimeric antisense oligonucleotides in in vivo cns studies of gene function

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994315A (en) * 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042178A2 (en) * 1999-01-13 2000-07-20 Dupont Pharmaceuticals Company Antagonist blockade of crf2 receptors for the treatment of psy chiatric disorders and the use of chimeric antisense oligonucleotides in in vivo cns studies of gene function

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HEINRICHS S C ET AL: "CORTICOTROPIN-RELEASING FACTOR CRF1, BUT NOT CRF2, RECEPTORS MEDIATE ANXIOGENIC-LIKE BEHAVIOR", REGULATORY PEPTIDES, ELSEVIER SCIENCE BV, NL, vol. 71, no. 1, 1997, pages 15 - 21, XP000907396, ISSN: 0167-0115 *
POULSEN S-A ET AL: "ADENOSINE RECEPTORS: NEW OPPORTUNITIES FOR FUTURE DRUGS", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 6, 1998, pages 619 - 641, XP000985735, ISSN: 0968-0896 *
See also references of WO0051621A1 *

Also Published As

Publication number Publication date
WO2000051621A1 (en) 2000-09-08
JP2002537792A (en) 2002-11-12
KR20020068262A (en) 2002-08-27
EP1165093A1 (en) 2002-01-02
CA2366055A1 (en) 2000-09-08
CN1348376A (en) 2002-05-08
BR0009247A (en) 2001-11-20
AU3512300A (en) 2000-09-21
IL145034A0 (en) 2002-06-30
MXPA01008870A (en) 2004-08-12

Similar Documents

Publication Publication Date Title
GB9903124D0 (en) An authentication method
GB9918348D0 (en) Location finding system and method
HK1035243A1 (en) Method and apparatus for executing prefetch instructions.
IL136155A0 (en) Data processing method
GB9911956D0 (en) Electrosurgery system and method
HK1042357A1 (en) Viewpoint control device and method
AU1674702A (en) Implanted sensor processing system and method
GB0118394D0 (en) Radiation treatment system and method
EP1260051A4 (en) System and method for secure electronic fund transfers
EP1146912A4 (en) Method for improved radiation therapy
HK1048373A1 (en) An access control method
IL145034A0 (en) Method for validating/invalidating target(s) and pathways
PL343990A1 (en) Method fo carrying out an aldolic condensation
GB9900070D0 (en) Control method
IL149270A0 (en) System and method for secure electronic transactions
IL139936A0 (en) Gene therapy method
GB0229834D0 (en) Target and method
EP1079335A4 (en) Bill processor and its controlling method
EP1053349A4 (en) Methods for identifying therapeutic targets
GB0026109D0 (en) An analysis method
SG108228A1 (en) Accurate processing through procedure validation in software controlled environment
GB9916569D0 (en) Apparatus and method for sensing metal ions
IL150268A0 (en) Method and system for detecting radiation
GB9928112D0 (en) Electronic payment method
GB0221222D0 (en) Method for electronic transactions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010918

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20020611

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041001